The US Justice Department filed a lawsuit to block a $570 million deal in the corporate travel market over antitrust concerns ...

Every investor in Silence Therapeutics plc ( NASDAQ:SLN) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 44% to be precise, ...

Scientists have developed inhalable lung cancer therapeutics utilizing mucoadhesive proteinic nanoparticles.

Boost productivity with these essential Microsoft Outlook tips. Learn how to organize your inbox, automate tasks, and ...

Context Therapeutics (NASDAQ:CNTX – Get Free Report) was upgraded by Citizens Jmp to a “strong-buy” rating in a note issued ...

Lung cancer remains one of the deadliest cancers globally. Non-small cell lung cancer (NSCLC), which accounts for 85% of all lung cancer cases, is particularly challenging to treat due to difficulties ...

Light Horse Therapeutics Inc., a developer of first-in-class small molecule therapeutics, today announced a $62 million Series A financing. The financing was led by founding investor Versant Ventures ...

Light Horse Therapeutics Inc., a developer of first-in-class small molecule therapeutics, announced a multi-target collaboration with Novartis to identify and develop potentially first-in-class ...

Fintel reports that on January 8, 2025, JMP Securities initiated coverage of Context Therapeutics (NasdaqCM:CNTX) with a ...

The discovery of a new type of stem cell in the brain could usher in better treatments for the deadliest brain tumor.

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...